Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma reports developments tied to its next-generation chimeric antigen receptor, or CAR T-cell, therapy pipeline for patients with cancer. The company’s recurring updates center on ronde-cel, an autologous dual-targeting CD19/CD20 CAR T-cell product candidate for large B-cell lymphoma, and LYL273, a GCC-targeted CAR T-cell product candidate for metastatic colorectal cancer and other GCC-expressing cancers.
Company news also covers clinical-trial activity, FDA designation updates, manufacturing capabilities at the LyFE Manufacturing Center, quarterly financial results, equity financing activity, licensing transactions, investor-conference participation and executive or governance changes.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) has announced the pricing of its initial public offering (IPO) of 25,000,000 shares at $17.00 per share, aiming to raise approximately $425 million before expenses. The IPO is set to commence trading on Nasdaq on June 17, 2021, and is expected to close on June 21, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 3,750,000 additional shares. Goldman Sachs & Co. LLC and others are leading the offering.